DRMA
Dermata Therapeutics, Inc.
There isn't enough reported data to score DRMA yet.
DRMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
DRMA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
DRMA PE Valuation
DRMA has no meaningful PE right now: it lost money over the past year.
DRMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect DRMA's losses to shrink, with revenue growing.
DRMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.17 | +$40.19 |
| Q2 2026 | -$7.27 | +$52.99 |
| Q1 2026 | -$8.19 | +$71.90 |
| Q4 2025 | -$12.21 | +$133.97 |
| Q3 2025 | -$46.36 | -689% |
| Q2 2025 | -$60.26 | -$2.68 |
| Q1 2025 | -$80.09 | +$50.49 |
| Q4 2024 | -$146.18 | +$254.32 |
DRMA is still losing money, but far less than before: $6.17 per share over the past year, against $400.50 at its worst in late 2023.
DRMA Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3856% | N/A |
DRMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.7M | -$898.9K |
| Q1 2026 | -$2.5M | -$545.7K |
| Q4 2025 | -$1.3M | +$1.6M |
| Q3 2025 | -$1.8M | +$1.6M |
| Q2 2025 | -$2.7M | -$564.5K |
| Q1 2025 | -$1.9M | +$770.4K |
| Q4 2024 | -$2.9M | -$1.8M |
| Q3 2024 | -$3.4M | -$1.6M |
DRMA has burned cash in almost every quarter: −$8M over the past year, against −$11M the year before.
DRMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +1.1M shares |
| 1 year | +399% | +4.1M shares |
| 3 years | +23981% | +5.1M shares |
| 5 years | +157279% | +5.1M shares |
DRMA has 5M diluted shares, up 399% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DRMA Net Leverage
DRMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DRMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 11.7 | Oversold |
DRMA's weekly RSI is 26 (oversold) and its Stochastic is 12 (oversold).
DRMA PE vs Healthcare Sector
| Metric | DRMA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DRMA has no meaningful PE right now: it lost money over the past year.
DRMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.89 | 26% below |
| 20 week MA | $1.12 | 41% below |
| 50 week MA | $1.40 | 53% below |
| 100 week MA | $4.63 | 86% below |
| 200 week MA | $79.3 | 99% below |
DRMA is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
DRMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12,456.0 | $5,088.0 | -59% |
| 2022 | $5,088.0 | $436.6 | -91% |
| 2023 | $436.6 | $91.5 | -79% |
| 2024 | $91.5 | $13.3 | -85% |
| 2025 | $13.3 | $1.86 | -86% |
| 2026 YTD | $1.86 | $0.66 | -65% |
DRMA has finished every year since 2021 lower, and it's down 65% so far in 2026.